Screening for Vulnerability in the Elderly Supported at the Oscar Lambret Centre
|ClinicalTrials.gov Identifier: NCT01415258|
Recruitment Status : Completed
First Posted : August 11, 2011
Last Update Posted : May 16, 2012
The objective of this study is to uncover the prevalence of vulnerability among patients aged ≥ 70 coming to the medical oncology division of the Oscar Lambret Centre, according to the short screening test Vulnerable Elders Survey 13 (VES-13).
The objective is to better understand the value of routine screening of patients before the consultation, it was proposed as a secondary objective of this study to assess the correlation between the identification of the vulnerability in the screening test VES-13 and the identification made by the clinician during the consultation. The correlation between VES-13 and opinion of the clinician for three categories of patients (self - intermediate - fragile) will also be studied.
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||209 participants|
|Official Title:||Screening for Vulnerability in the Elderly Supported at the Oscar Lambret Centre|
|Study Start Date :||March 2011|
|Primary Completion Date :||August 2011|
|Study Completion Date :||April 2012|
- To assess the Vulnerable Elders Survey score (VES-13) [ Time Frame: Within 3 months after recruitment ]A patient is identified vulnerable if the score is ≥ 3
- To assess the correlation between the VES-13 score and the vulnerability judged by a clinical expert [ Time Frame: Within 3 months after recruitment ]A patient will be identified as vulnerable if he/she belongs to the "intermediate" or "frail" category. The Kappa coefficient of agreement will be used to correlate the VES-13 score and clinical observations.
- To measure the muscle strength using the grip strength test [ Time Frame: Within 3 months after recruitment ]Hand Dynamometer Range values : 0-90
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01415258
|Oscar Lambret Anti-Cancer Centre|
|Lille cedex, France, 59020|
|Principal Investigator:||Véronique SERVENT, MD||Oscar Lambret Anti-Cancer Centre|